SecBot SecBot
8-K ·Filed May 12, 2026

TELA

TELA Bio, Inc.
MIXED
Impact 4/10
Horizonweeks Processed6mo ago SEC0001104659-26-059393
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Revenue growth decelerated sharply to 3% from prior quarters' 16-19% annual growth, and the company is burning ~$11M/quarter with only $39.5M cash. Monitor Q2 2026 revenue (~$20.0M guided) and whether the OviTex LTR launch and European expansion can re-accelerate growth; the cash runway is limited without a capital raise.

DirectionMixed
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

TELA Bio reported Q1 2026 revenue of $19.1M (+3% YoY), slightly above the $19.0M preliminary estimate, and a net loss of $12.3M ($-0.21 per share), which widened from $11.3M in Q1 2025. The company reiterated full-year 2026 revenue guidance of at least 8% growth and guided Q2 2026 revenue to ~$20.0M, but the 3% quarterly growth rate is a deceleration from prior periods and operating losses remain elevated, making this a mixed result.

Key Financial Metrics

EPS
−$0.21
est −$0.14 · -50.0%
Revenue
$19.1M
est $19.0M · +0.3% · +2.9% YoY
Rating
in line
Guidance
FY2026 at least 8% growth over FY2025; Q2 2026 ~$20.0M
maintained
Gross Margin
65.7%

Key Facts

  • Q1 2026 revenue of $19.1M, up 3% YoY from $18.5M, in line with the $19.0M preliminary estimate
  • Net loss widened to $12.3M ($-0.21 per share) from $11.3M ($-0.25 per share) in Q1 2025
  • Gross margin declined to 65.7% from 67.6% YoY due to higher excess/obsolete inventory charges
  • Operating expenses flat at $23.0M; loss from operations unchanged at $10.5M
  • Cash and cash equivalents fell to $39.5M from $50.8M at year-end 2025, a burn of ~$11.3M
  • Full-year 2026 revenue guidance reiterated at 'at least 8% growth' over 2025; Q2 2026 revenue guided to ~$20.0M
  • European revenue grew 41% YoY; U.S. commercial launch of OviTex LTR initiated April 1, 2026
  • Board refreshment plan announced in April 2026 with several director resignations and new appointments effective June 9, 2026

Financial Impact

Revenue $19.1M (+3% YoY), net loss $12.3M, cash burn $11.3M in Q1

revenuegross marginnet losscash position

Risk Factors

  • Cash burn rate of ~$11M/quarter with $39.5M on hand implies less than 4 quarters of runway
  • Revenue growth deceleration to 3% from prior double-digit rates signals potential market saturation or competitive pressure
  • Gross margin compression from 67.6% to 65.7% due to inventory obsolescence charges
  • Board refreshment with multiple director departures creates near-term governance uncertainty

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-059393
Document: tm2614218d1_8k.htm0001104659-26-059393
Document: tm2614218d1_ex99-2.htm0001104659-26-059393
Document: 0001104659-26-059393-index-headers.html0001104659-26-059393
Document: 0001104659-26-059393-index.html0001104659-26-059393
Document: 0001104659-26-059393.txt0001104659-26-059393
8-K Data (Synthetic)0001104659-26-059393

Track record

20 reports on TELA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +18.61% at T+5 after the Aug 10, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $0.7610 Now $0.7620 +0.13% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.8200 Now $0.7620 −7.07% settles Nov 23
  3. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.8201 Now $0.7620 −7.08% settles Nov 23
  4. Nov 10, 20266d ago S-3 Bearish 5/10 Entry $0.9418 Now $0.7620 +19.09% settles Nov 18
  5. Nov 10, 20266d ago Press Release Bearish 5/10 Entry $0.9418 Now $0.7620 +19.09% settles Nov 18
  6. Oct 27, 202620d ago Press Release Neutral 2/10 Entry $0.9760 to $0.8378 Now $0.7620 −21.93% ▼ −14.16% −13.45% vs SPY
  7. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.07 to $1.10 Now $0.7620 −28.79% ▲ +2.34% +3.32% vs SPY
  8. Oct 5, 20266w ago 8-K Bullish 5/10 Entry $1.14 to $1.08 Now $0.7620 −33.16% ▼ −5.26% −5.69% vs SPY
  9. Aug 31, 202611w ago 8-K Mixed 6/10 Entry $0.7380 to $0.8301 Now $0.7620 +3.25% ▲ +12.48% +12.62% vs SPY
  10. Aug 10, 202614w ago 8-K Bearish 7/10 Entry $0.7900 to $0.6430 Now $0.7620 +3.54% ▲ +18.61% +18.20% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026